Lenvatinib for advanced parathyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether the drug lenvatinib can shrink or slow advanced parathyroid cancer that cannot be removed by surgery. Lenvatinib is a targeted therapy that blocks blood vessel growth to tumors, which may help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have parathyroid cancer confirmed by a biopsy.
- Your cancer is advanced or has spread and cannot be fully removed with surgery.
- You have at least one tumor that can be measured on a scan.
- You are 19 years or older.
- You are generally able to do daily activities (ECOG 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
This trial tests a new combination of lenvatinib (a targeted therapy) plus standard chemotherapy for pancreatic neuroendocrine tumors that have spread to the liveraging after first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This trial tests a combination of two drugs, sinibolimab (an immunotherapy) and lenvatinib (a targeted therapy), given before surgery to shrink locally advanced thyroid cancer that cannot be fully removed. The goal is to make the tumor removable and improve outcomes.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
Hear when a new Parathyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.